Hoover Pharmaceuticals (Pvt.) Ltd
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer established in 2009 and focused on quality, regulatory compliance and branded pharmaceutical products.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Hoover Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 16, Zain Park Industrial Area, Lahore, Pakistan
- Website
- hooverpharm.com ↗
- Official contact
- Contact page ↗
- Corporate source details checked
- 25 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Blucip | Ciprofloxacin | 500 mg | Tablet | 1x10's | 065925 | PKR 408.67 | PKR 40.87/tablet | Near median |
| Blucip | Ciprofloxacin | 250 mg | Tablet | 1x10's | 065926 | PKR 247.10 | PKR 24.71/tablet | Near median |
| Clingard | Clindamycin | 10 mg | Gel | 10gm | 064533 | PKR 437.18 | PKR 43.72/g | 19% above median |
| Daymac | Clindamycin | 1% | Gel | 30gm | 062452 | PKR 513.22 | PKR 17.11/g | No comparator |
| Daymac | Clindamycin | 10 mg/mL | Lotion | 30ml | 091548 | PKR 205.99 | PKR 6.87/mL | Near median |
| Daymac VGL | Clindamycin | 20 mg/g | Cream | 40gm | 077210 | PKR 545.53 | PKR 13.64/g | 10% below median |
| Delvocin | Levofloxacin | 500 mg | Tablet | 1x10's | 065923 | PKR 532.22 | PKR 53.22/tablet | 33% below median |
| Delvocin | Levofloxacin | 250 mg | Tablet | 1x10's | 065924 | PKR 380.16 | PKR 38.02/tablet | 21% below median |
| Emevid | Ofloxacin | 200 mg | Tablet | 10's | 077022 | PKR 218.59 | PKR 21.86/tablet | Near median |
| Emevid | Ofloxacin | 400 mg | Tablet | 10's | 077023 | PKR 285.12 | PKR 28.51/tablet | 8% below median |
| Erthowel | Erythromycin | 200 mg/5 mL | Suspension | 60ml | 100639 | PKR 47.43 | PKR 0.79/mL | 34% below median |
| Fungex | Itraconazole | 100 mg | Capsule | 1x4's | 062478 | PKR 570.24 | PKR 142.56/capsule | Near median |
| Hooxim | Cefixime | 400 mg | Capsule | 5's | 109544 | PKR 564.12 | PKR 112.82/capsule | Near median |
| Hooxim | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 109545 | PKR 314.81 | PKR 10.49/mL | Near median |
| Hooxim | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 109546 | PKR 385.25 | PKR 12.84/mL | Near median |
| Indosef | Ceftriaxone | 250 mg | Injection | 1's | 099916 | PKR 154.54 | PKR 154.54/vial/unit | 20% below median |
| Indosef | Ceftriaxone | 500 mg | IM injection | 1's | 099917 | PKR 260.12 | PKR 260.12/vial/unit | 21% below median |
| Indosef | Ceftriaxone | 1 g | Injection | 1's | 099918 | PKR 491.17 | PKR 491.17/vial/unit | 19% below median |
| Kinnate external prepation | Chlorhexidine gluconate | 15 mg | Solution | 1000ml | 092287 | PKR 497.29 | PKR 0.50/mL | No comparator |
| Klarox | Clarithromycin | 125 mg/5 mL | Dry suspension | 60ml | 089429 | PKR 423.88 | PKR 7.06/mL | Near median |
| Lenzonon powder | Linezolid | 100 mg/5 mL | Suspension | 60ml | 087572 | PKR 665.28 | PKR 11.09/mL | Near median |
| Lotriderm | Clotrimazole | 100 mg | Vaginal tablet | 6's | 062445 | PKR 114.05 | PKR 19.01/tablet | 9% below median |
| Lotriderm | Clotrimazole | 1% | Vaginal cream | 35gm | 062450 | PKR 190.34 | PKR 5.44/g | No comparator |
| Mitex | Permethrin | 5% | Cream | 30gm | 065910 | PKR 116.98 | PKR 3.90/g | Near median |
| Mitex | Permethrin | 5 g/100 mL (5%) | Lotion | 100ml | 087565 | PKR 258.68 | PKR 2.59/mL | No comparator |
| Mitex | Permethrin | 5 g/100 mL | Lotion | 60ml | 087565 | PKR 152.06 | PKR 2.53/mL | No comparator |
| Mycostin | Terbinafine | 1 % | Cream | 10gm | 077208 | PKR 319.33 | PKR 31.93/g | 11% above median |
| Mycostin | Terbinafine | 250 mg | Tablet | 1x10's | 098383 | PKR 765.07 | PKR 76.51/tablet | 10% below median |
| Poviderm | Povidone-iodine | 5% | Gel | 10gm | 069183 | PKR 81.73 | PKR 8.17/g | No comparator |
| Poviderm | Povidone-iodine | 10 g/100 mL | Solution | 60ml | 089427 | PKR 154.30 | PKR 2.57/mL | 42% above median |
| Poviderm | Povidone-iodine | 10 g/100 mL | Solution | 450ml | 089427 | PKR 814.60 | PKR 1.81/mL | 30% below median |
| Poviderm | Povidone-iodine | 5 % | Solution | 75ml | 094559 | PKR 105.82 | PKR 1.41/mL | No comparator |
| Rapilox | Moxifloxacin | 400 mg | Tablet | 1x5's | 062467 | PKR 902.88 | PKR 180.58/tablet | Near median |
| Sentobe | Silver sulfadiazine | 1 % | Cream | 25gm | 065929 | PKR 97.09 | PKR 3.88/g | 10% above median |
| Sentobe | Silver sulfadiazine | 10 mg/g (1%) | Cream | 50gm | 065929 | PKR 361.15 | PKR 7.22/g | 66% above median |
| Trazacin | Azithromycin | 250 mg | Tablet | 1x6's | 062468 | PKR 285.12 | PKR 47.52/tablet | Near median |
| Trazacin | Azithromycin | 200 mg/5 mL | Dry suspension | 15ml | 089428 | PKR 313.63 | PKR 20.91/mL | Near median |
| Trazacin | Azithromycin | 500 mg | Tablet | 1x6 | 106162 | PKR 393.26 | PKR 65.54/tablet | 23% below median |
| Triflucan | Fluconazole | 50 mg/5 mL | Dry suspension | 35ml | 086351 | PKR 399.17 | PKR 11.40/mL | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.